Immutep Ltd

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

SYDNEY, AUSTRALIA, Sept. 06, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland to enable an investigator-initiated open label Phase II clinical trial. The trial will evaluate Immutep's lead product candidate efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) in up to 40 patients with select soft tissue sarcoma (STS).

Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

SYDNEY, AUSTRALIA, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 7116547) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the Japanese Patent Office.

Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

SYDNEY, AUSTRALIA, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce new interim data from 2nd line NSCLC patients (Part B) in the Phase II TACTI-002 trial. The data was presented as part of the electronic poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) being held in Vienna, Austria and is also available on the Company's website.

Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled “Anti-LAG-3 Antibodies” by the Japanese Patent Office.

Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

SYDNEY, AUSTRALIA, June 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new data from second line non-small cell lung cancer patients (Part B) in the Phase II TACTI-002 trial has been selected for a poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) taking place in-person and online from 6-9 August 2022 in Vienna, Austria.

Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer

Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event.

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

SYDNEY, AUSTRALIA, June 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces new data from 1st line NSCLC patients (Part A) of the Phase II TACTI-002 trial evaluating Immutep's lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in 114 patients.

Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, will host a global webcast to discuss new data from 1st line non-small cell lung cancer (NSCLC) patients participating in its Phase II TACTI-002 trial including an analyst Q&A.

Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

SYDNEY, AUSTRALIA, May 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce new interim data from Part A of the Phase II TACTI-002 trial in 1st line NSCLC has been published today in an abstract at the American Society of Clinical Oncology's (ASCO) 2022 Annual Meeting.

Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited to present at investor conferences, as outlined below.

Immutep to Present at Investor Conferences

SYDNEY, AUSTRALIA, May 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limi t ed (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today the appointment of four new members to the Company's Clinical Advisory Board (CAB).

Immutep Appoints Leading Oncologists to its Clinical Advisory Board

SYDNEY, AUSTRALIA, May 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, today reports new biomarker and exploratory analysis data from its Phase IIb AIPAC trial. The data was presented at ESMO's Breast Cancer Congress in a poster presentation which is available on ESMO's website and at https://www.immutep.com/investors-media/presentations.html.

Immutep Presents New and Significant Data from the AIPAC Study

SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited  (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim data from first line non-small cell lung cancer patients (Part A) of the Phase II TACTI-002 trial has been selected for a prestigious Oral Presentation at the American Society of Clinical Oncology's (ASCO) 2022 Annual Meeting.

Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting

SYDNEY, AUSTRALIA, March 30, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim data in 2nd line metastatic NSCLC from its Phase II TACTI-002 trial. The data was published in a poster presentation at ESMO's European Lung Cancer Congress (ELCC) 2022 in Prague, Czech Republic and is also available on the Company's website:

Immutep's Efti in Combination with MSD's Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

SYDNEY, AUSTRALIA, March 24, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that new interim data from 2nd line NSCLC patients (Part B) of its phase II TACTI-002 trial has been published in an abstract today in advance of ESMO's European Lung Cancer Congress (ELCC) 2022. ELCC 2022 will now be taking place in a virtual only format from 30 March 2022 to 2 April 2022.

Immutep Announces Publication of TACTI-002 Abstract at ESMO's European Lung Cancer Congress 2022

FDA approval of Bristol Myers Opdualag/relatlimab anti-LAG3 carries positive implications for LAG3 pure-play Immutep's entire pipeline.

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data from its Phase IIb AIPAC trial at ESMO's Breast Cancer Congress 2022, which will take place onsite in Berlin, Germany and virtually on 3-5 May 2022.

Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO's Breast Cancer Congress 2022

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) --   Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. 7030750 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office.

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

SYDNEY, AUSTRALIA, March 10, 2022 (GLOBE NEWSWIRE) --   Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical development program for lead product candidate, eftilagimod alpha (efti or IMP321), in metastatic breast cancer (MBC).

Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer

SYDNEY, AUSTRALIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immutep Limited  (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited present at investor conferences, as outlined below.

Immutep to Present at Healthcare Investor Conferences

SYDNEY, AUSTRALIA, Feb. 18, 2022 (GLOBE NEWSWIRE) --   Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data is scheduled to be presented at ESMO's European Lung Cancer Congress (ELCC) 2022 which will take place in-person in Prague, Czech Republic and virtually from 30 March to 2 April 2022, Central European Summer Time (CEST).

Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO's European Lung Cancer Congress 2022

SYDNEY, AUSTRALIA, Feb. 11, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 2016205983) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the Australian Patent Office.

Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor

SYDNEY, AUSTRALIA, Jan. 31, 2022 (GLOBE NEWSWIRE) --   Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced today that Immutep CEO Marc Voigt has been invited to participate in the following investor conferences scheduled to take place in February 2022.

Immutep to Present at February Investor Conferences

SYDNEY, AUSTRALIA, Dec. 16, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has signed a Manufacturing Service Agreement (MSA) with Northway Biotech, an end-to-end biopharmaceutical contract development and manufacturing organisation (CDMO), to manufacture IMP761 ahead of clinical testing.

Immutep Advances IMP761 Manufacturing

SYDNEY, AUSTRALIA, Dec. 02, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the first five patients have been treated in the INSIGHT-003 study.

News for Immutep Ltd Stock (IMMP)